Vitura Health Lands Top-5 Cannabis Supplier Deal Worth Up to $15M Annually
Vitura secures national distribution deal with MedReleaf Australia
Vitura Health Limited (ASX: VIT) has entered into a binding commercial distribution agreement with MedReleaf Australia, bringing one of the country’s top-5 medicinal cannabis suppliers by volume onto the Canview platform for the first time. The partnership positions MedReleaf’s full product portfolio across Vitura’s Canview ecosystem, which reaches more than four in five Australian pharmacies actively dispensing medicinal cannabis, representing approximately 4,700 registered locations nationwide.
MedReleaf, a wholly owned subsidiary of Canadian-based Aurora Cannabis (NASDAQ: ACB), supplies pharmaceutical-grade medicinal cannabis products under five brands: MedReleaf, IndiMed, Aurora, Whistler Cannabis Co., and CraftPlant. The distribution agreement marks the first time MedReleaf’s complete range will be accessible through Canview and distributed via Burleigh Heads Cannabis’ nationwide network, expanding patient and prescriber access across Vitura’s established infrastructure.
The partnership carries no minimum purchase commitments, reducing downside risk for Vitura whilst creating upside optionality through demand-driven growth. This structure allows the company to capture revenue from an established supplier portfolio without capital exposure or volume guarantees.
Revenue potential from the partnership
Based on current market conditions and management estimates, Vitura believes the agreement has the potential to contribute up to approximately $15 million in additional annual revenue across the company’s distribution channels over time. This estimate is not a forecast or guarantee and remains subject to patient demand, product uptake, regulatory settings, and competitive dynamics.
If achieved, this level of activity would position MedReleaf among the larger suppliers distributed by the company. The flexible commercial structure, absent of minimum purchase obligations, enables Vitura to scale revenue in line with market adoption without downside exposure.
Ryan Tattle, Chief Revenue Officer
“This strategic partnership with MedReleaf will deliver clear commercial outcomes for both parties, including the introduction of new products and formats over time.”
When big ASX news breaks, our subscribers know first
How medicinal cannabis distribution works in Australia
Platforms like Canview function as intermediaries connecting suppliers, prescribers, pharmacies, and patients within Australia’s tightly regulated medicinal cannabis framework. Products are classified as Schedule 8 controlled substances under Therapeutic Goods Administration (TGA) oversight, requiring electronic prescription management, dispensing controls, and audit trails throughout the supply chain.
Vitura operates two state-of-the-art distribution centres in Melbourne and the Gold Coast, both fully licensed to handle products under Schedules 2, 3, 4, 8, and 9. This licensing breadth positions the company to distribute not only medicinal cannabis but also other controlled therapeutic products, including psychedelics through its Cortexa joint venture with PharmAla Biotech.
The Canview platform integrates software-as-a-service (SaaS) providers covering inventory control, invoicing, customer management, and analytics. Australian doctors can integrate their patient management systems directly with Canview, generating electronic prescriptions without re-entering patient details. Prescriptions are sent to the Canview patient app, where patients manage treatment and submit scripts to any of the approximately 4,700 registered pharmacies for dispensing.
Vitura’s infrastructure and pharmacy network create a competitive moat. Adding major suppliers like MedReleaf strengthens market position without proportional cost increases, as the platform’s fixed technology and distribution assets scale efficiently with volume growth.
Vitura’s growth trajectory and clinic expansion
The MedReleaf distribution agreement fits within Vitura’s broader growth trajectory, which has seen revenue climb from $21.7 million in FY21 to $124 million in FY24. This expansion reflects both organic growth in distribution and strategic acquisitions across the company’s Specialty Clinics Division.
In November 2024, Vitura formed a joint venture with Flora Holdings to acquire the assets of the Releaf Group, adding 30,000 patients across five physical clinic and dispensary locations in Victoria, New South Wales, and Queensland. Progress continues toward re-engaging this patient base, with Releaf positioned to capitalise on evolving regulatory requirements including telehealth and Department of Veterans’ Affairs (DVA) protocols.
In February 2025, the company acquired Candor Medical, an online telehealth clinic providing access to an additional 15,000 active patients. Vitura has since confirmed Candor’s integration with legacy brands Cannadoc and CDA Clinics, consolidating patient management and prescribing workflows across the group’s clinic ecosystem.
| Metric | FY21 | FY24 |
|---|---|---|
| Revenue | $21.7m | $124m |
| Pharmacies on Canview | — | ~4,700 |
| Releaf patients | — | 30,000 |
| Candor patients | — | 15,000 |
The combined patient base across Releaf, Candor, Cannadoc, and CDA Clinics positions Vitura with significant prescribing volume across its integrated clinic network, whilst the Canview platform distributes approximately 600 product SKUs from roughly 70 international and domestic brands.
Strategic positioning in a consolidating market
Chief Revenue Officer Ryan Tattle noted the supplier and distribution landscape in Australia continues to “rearrange and consolidate,” positioning Vitura as a beneficiary of industry consolidation due to its established infrastructure. The company’s dual distribution centres, broad scheduling licences, and integrated technology platform create barriers to entry for competitors whilst enabling efficient onboarding of new supplier relationships like MedReleaf.
Releaf is positioned to capitalise on evolving regulatory requirements, including telehealth protocols and DVA prescribing pathways, which favour established clinic networks with compliance infrastructure and patient management systems already in place.
Vitura’s competitive advantages in a consolidating market include:
- Market-leading pharmacy network with 4,700+ registered locations actively dispensing medicinal cannabis
- Dual distribution centres in Melbourne and the Gold Coast with licensing across Schedules 2, 3, 4, 8, and 9
- Integrated clinic ecosystem spanning Releaf, Candor, CDA Clinics, and Cannadoc with combined patient base exceeding 45,000
- Technology platform connecting prescribers, patients, and pharmacies through end-to-end prescription and dispensing workflows
The next major ASX story will hit our subscribers first
What’s next for Vitura
Vitura expects strong revenue growth to continue across all business divisions, with the MedReleaf distribution agreement adding to existing momentum. Re-engagement of the Releaf patient base remains underway, whilst the recently integrated Candor Medical, Cannadoc, and CDA Clinics operations provide additional prescribing volume across the group’s distribution channels.
Beyond medicinal cannabis, Vitura’s Cortexa joint venture with PharmAla Biotech positions the company in psychedelics distribution, targeting supply of GMP MDMA and GMP psilocybin for research and therapeutic use. This diversification demonstrates the scalability of Vitura’s licensing and distribution infrastructure beyond Schedule 8 medicinal cannabis products.
The company operates multiple revenue drivers across distribution, clinics, and emerging therapeutic segments. The MedReleaf distribution agreement represents one component of a broader growth strategy anchored in platform scalability, supplier diversification, and clinic integration.
Ryan Tattle, Chief Revenue Officer
“In an evolving and competitive market, Vitura has experienced strong revenue growth across all businesses over the last five years, growing from $21.7m in FY21 to $124m last financial year. The Company expects this strong growth to continue and the new distribution agreement with MedReleaf will certainly add to that.”
Want the Next Healthcare Breakout in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements the moment they drop.